Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion

The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2011 by Hospital Centre Biel/Bienne.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Brahms AG
Information provided by:
Hospital Centre Biel/Bienne
ClinicalTrials.gov Identifier:
NCT00696605
First received: June 10, 2008
Last updated: June 22, 2011
Last verified: June 2011
  Purpose

The are 2 principal goals in this study:

  1. To measure plasma copeptin levels in healthy subjects and to correlate them with plasma AVP concentrations and urine osmolalities in iso-, hypo-, and hyperosmolar states.
  2. To measure plasma copeptin concentrations in patients with chronic renal failure under the same conditions described above, in order to characterize the impact of renal function on circulating copeptin levels in correlation to plasma AVP and urine osmolality.

Condition
Hypoosmolality
Hyperosmolality
Renal Failure

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Assessment of Circulating Copeptin Levels in Healthy Subjects and Patients With Renal Insufficiency After Oral Water Load and Hypertonic Saline Infusion

Resource links provided by NLM:


Further study details as provided by Hospital Centre Biel/Bienne:

Estimated Enrollment: 35
Study Start Date: July 2008
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Healthy volunteers; patients with chronic renal failure

Criteria

Inclusion Criteria:

  • chronic renal failure grade I through IV
  • healthy age-matched controls

Exclusion Criteria:

  • chronic renal failure grade V
  • heart failure
  • liver disease
  • nephrotic syndrome
  • anemia (hemoglobin level < 100 g/L)
  • uncontrolled hypertension (systolic BP > 160 mmHg; diastolic BP > 95 mm Hg)
  • coexisting severe disease
  • known thyroid disease
  • known hypocortisolism
  • known hypercortisolism
  • known diabetes insipidus
  • pregnancy
  • lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00696605

Locations
Switzerland
Clinic of Internal Medicine, Hospital Center Recruiting
Biel/Bienne, Switzerland, 2501
Contact: Jonas Rutishauser, M.D.    +41323243438    j.rutishauser@unibas.ch   
Sponsors and Collaborators
Hospital Centre Biel/Bienne
Brahms AG
  More Information

No publications provided by Hospital Centre Biel/Bienne

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr. Jonas Rutishauser, Medical Clinic, Hospital Center Biel/Bienne, Switzerland
ClinicalTrials.gov Identifier: NCT00696605     History of Changes
Other Study ID Numbers: Swiss AVP-Copeptin Trial
Study First Received: June 10, 2008
Last Updated: June 22, 2011
Health Authority: Switzerland: Ethikkommission

Keywords provided by Hospital Centre Biel/Bienne:
Hypoosmolality
Hyperosmolality
Copeptin
Vasopressin

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on November 24, 2014